Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide in patients with cirrhosis
The bioavailability, pharmacokinetics, and pharmacodynamics of torsemide (10 mg orally and intravenously) were determined in a randomized crossover clinical trial with 12 patients with ascites caused by cirrhosis. Torsemide was rapidly absorbed with a bioavailability of 96.3% (confidence interval, 84% to 109%). Compared with healthy subjects, patients with cirrhosis exhibit a decrease in nonrenal clearance and increases in bioavailability, volume of distribution, renal clearance, elimination half-life, and percentage of the dose excreted into the urine. A greater proportion of the dose is delivered to the site of action over a more prolonged period of time. In spite of a shift of the pharmacodynamic curve to the right in patients with cirrhosis, there was no significant difference in natriuresis. Pharmacokinetic changes of torsemide in cirrhosis therefore compensate for the pharmacodynamic abnormality.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
1993 |
|---|---|
| Erschienen: |
1993 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:54 |
|---|---|
| Enthalten in: |
Clinical pharmacology and therapeutics - 54(1993), 1 vom: 15. Juli, Seite 90-7 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Schwartz, S [VerfasserIn] |
|---|
| Themen: |
Clinical Trial |
|---|
| Anmerkungen: |
Date Completed 19.08.1993 Date Revised 12.05.2019 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM08305216X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM08305216X | ||
| 003 | DE-627 | ||
| 005 | 20231222054053.0 | ||
| 007 | tu | ||
| 008 | 231222s1993 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0277.xml |
| 035 | |a (DE-627)NLM08305216X | ||
| 035 | |a (NLM)8330470 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Schwartz, S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide in patients with cirrhosis |
| 264 | 1 | |c 1993 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 19.08.1993 | ||
| 500 | |a Date Revised 12.05.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The bioavailability, pharmacokinetics, and pharmacodynamics of torsemide (10 mg orally and intravenously) were determined in a randomized crossover clinical trial with 12 patients with ascites caused by cirrhosis. Torsemide was rapidly absorbed with a bioavailability of 96.3% (confidence interval, 84% to 109%). Compared with healthy subjects, patients with cirrhosis exhibit a decrease in nonrenal clearance and increases in bioavailability, volume of distribution, renal clearance, elimination half-life, and percentage of the dose excreted into the urine. A greater proportion of the dose is delivered to the site of action over a more prolonged period of time. In spite of a shift of the pharmacodynamic curve to the right in patients with cirrhosis, there was no significant difference in natriuresis. Pharmacokinetic changes of torsemide in cirrhosis therefore compensate for the pharmacodynamic abnormality | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, U.S. Gov't, P.H.S. | |
| 650 | 7 | |a Diuretics |2 NLM | |
| 650 | 7 | |a Sulfonamides |2 NLM | |
| 650 | 7 | |a Torsemide |2 NLM | |
| 650 | 7 | |a W31X2H97FB |2 NLM | |
| 700 | 1 | |a Brater, D C |e verfasserin |4 aut | |
| 700 | 1 | |a Pound, D |e verfasserin |4 aut | |
| 700 | 1 | |a Green, P K |e verfasserin |4 aut | |
| 700 | 1 | |a Kramer, W G |e verfasserin |4 aut | |
| 700 | 1 | |a Rudy, D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical pharmacology and therapeutics |d 1960 |g 54(1993), 1 vom: 15. Juli, Seite 90-7 |w (DE-627)NLM000015318 |x 1532-6535 |7 nnns |
| 773 | 1 | 8 | |g volume:54 |g year:1993 |g number:1 |g day:15 |g month:07 |g pages:90-7 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 54 |j 1993 |e 1 |b 15 |c 07 |h 90-7 | ||